Table 1.

Included studies

Study	Journal and year	Country	Descent, ethnicity, racea	Gene symbols(s)	Polymorphism(s) dbSNP ID	Case definition	Control definition	Cases genotyped, n	Controls genotyped, n
Allen-Brady et al76	Obstet Gynecol 2011	United States, The Netherlands	White and Northern European descent	LINC0108b ZFAT Intergenic Intergenic Intergenic COL18A1	rs1455311 rs1036819 rs430794 rs8027714 rs1810636 rs2236479	Surgically treated/recurrent POP with family history	Population controls	191	3036
Campeau et al59	Neurourol Urodyn 2011 (ICS abstract)	United States	Not stated	MMP1	rs1144393 rs498186 rs473509	Surgically treated POP	Hospital controls “without POP”	63	93
Chen et al55	Am J Obstet Gynecol 2010	United States	African American and Caucasian	LAMC1	rs10911193 rs20563 rs20558	POP stage >II	POP stage <II	165	246
Chen et al66	Int Urogynecol J 2008	Taiwan	Taiwanese	ESR1	rs17847075 rs2207647 rs2234693 rs3798577 rs2228480	POPQ ≥2	POPQ <2	88	153
Chen et al68	Acta Obstet Gynecol 2009	Taiwan	Taiwanese	PGR	rs500760 rs484389	POPQ ≥2	POPQ <2	87	150
Chen et al78	Am Soc Hum Genet 2013	United States	African American and Hispanic American	PRCPb	rs2086297	Symptomatic SUI	No SUI	≈3343	≈8183
Chen et al66	Int Urogynecol J 2008	Taiwan	Taiwanese	COL3A1	rs1800255 rs1801184	POPQ ≥2	POPQ <2	84	147
Chen et al64	Eur J Obstet Gynecol 2010	Taiwan	Taiwanese	MMP9	rs3918242 rs17576 rs2250889	POPQ ≥2	POPQ <2	92	152
Chen et al67	Eur J Obstet Gynecol 2008	Taiwan	Taiwanese	ESR2	rs2987983 rs1271572 rs944459 rs1256049 rs1255998	POPQ ≥2	POPQ <2	69	141
Cho et al45	Yonsei Med J 2009	Korea	Korean	COL1A1	rs1800012	Surgically treated POPQ ≥3	POPQ = 0	15	15
Choy et al69	ICS abstract 2007	Hong Kong	Chinese	EDN1	rs5370 rs10478694	POPQ ≥2	Hospital “normal’’ controls and HapMap Han Chinese controls	60 (rs5370) and 67 (rs10478694)	210
Cornu et al70	World J Urol 2011	France	Caucasian	ESR1 CYP17A1 CYP19A1 AR	rs2234693 rs743572 rs60271534 CAG repeat	Treated for UI (30 UUI, 107 SUI)	No UI or OAB	121	66
Feiner et al42	Int Urogynecol J 2009	Israel	Caucasian or Ashkenazi-Jewish	COL1a1	rs1800012	POPQ ≥3	POPQ <2	36	36
Ferrari et al44	Arch Gynecol Obstet 2012	Italy	Italian	COL1a1 MMP9 MMP1 MMP3	rs1800012 rs3918242 rs1799750 rs3025058	POPQ ≥2	POPQ <2	137	96
Ferreira et al38	Am J Obstet Gynecol 2011	Brazil	White or nonwhite	ADRB3	rs4994	Symptomatic OAB without severe SUI	No LUTS	49	169
Ferrell et al75	Reprod Sci 2009	United States	African American or Caucasian	LOXL1	rs16958477	POP stage ≥II	POP stage <II	137	130
Fu et al56	J Urol 2009 (AUA abstract)	United States	Not stated	LAMC1 LOXL1	rs10911193	POP stage ≥III	No POP or UI	61	33
Honda et al37	Neurourol Urodyn 2014	Japan	Japanese	ADRb3	rs4994	Symptomatic OAB	No OAB	100	101
Jeon et al51	J Urol 2009	Korea	Korean	COL3a1	rs111929073	POPQ ≥2	POPQ <2 and no SUI	36	36
Kim et al74	Eur J Obstet Gynecol Reprod Biol 2014	Korea	Korean	GSTM1 GSTT1 GSTP1	Null Null rs1695	POPQ ≥3	POPQ <2	189	156
Kim et al73	Menopause 2014	Korea	Korean	PARP1	rs1136410	POPQ ≥3	POPQ <2	185	155
Lince et al50	Int Urogynecol J 2014	The Netherlands	≈99% Dutch	COL3a1	rs1800255	POPQ ≥2	POPQ <2	272	82
Martins et al52	Neurourol Urodyn 2011	Brazil	White or nonwhite	COL3a1	rs111929073	POP stage ≥III	POP stage <II	107	209
Noronha et al71	J Investig Med 2010	Brazil	Predominant European/white	HTR2A	rs6313	Symptomatic UI	Self-reported continent women, and population controls	68	849
Ozbek et al72	J Obstet Gynaecol Res 2013	Turkey	Caucasian	LOXL1	rs2165241 rs3825942 rs1048661	Symptomatic SUI	No UI	93	75
Rodrigues et al41	Int Urogynecol J 2008	Brazil	White or nonwhite	COL1a1	rs1800012	POP stage ≥III	POP stage <II and no SUI	107	209
Romero and Jamison65	J Pelv Med Surg 2008	United States	White	MMP1 MMP2 MMP3 MMP8 MMP9 MMP10 MMP11 TIMP1 TIMP3	rs2071230 rs7201 rs679620 rs35866072 rs17576 rs17435959 rs738789 rs4898 rs2016293	POPQ ≥3	POPQ <2 and no UI	45	38
Sioutis et al47	Int Urogynecol J 2011	Greece	Greek	COL1a1	rs1800012	SUI confirmed with urodynamics and positive pad test, and postmenopausal	Healthy postmenopausal	45	45
Skorupski43	Int Urogynecol J 2009 (IUGA abstract)	Poland	Polish	COL1a1	rs1800012	POPQ ≥2	POPQ <2 and no UI	120	97
Skorupski et al46	Am J Obstet Gynecol 2006	Poland	Polish	COL1a1	rs1800012	SUI confirmed with urodynamics and positive pad test	POPQ <2 and no UI	50	50
Skorupski et al61	Ginekol Polska 2010	Poland	Polish	MMP1 MMP3	rs1799750 rs3025058	POPQ ≥2	POPQ <2	132	133
Takeda et al36	ICS Abstract 2002	Japan	Japanese	ADRb3 ADRA1A	rs4994 rs1048101	Any LUTS (includes mixed group of women and men)	No LUTS	27	17
Velez Edwards et al77	Am Soc Hum Gen 2013	United States	African American and Hispanic American	CPEb Intergenic	rs28573326 rs113518633	POP stage ≥I	POP stage = 0	1427	1274
Vishwajit et al60	ICS abstract 2009	United States	Not stated	MMP1	rs1799750	SUI with varying POP	Neither SUI nor POP	40	15
Wu et al54	Am J Obstet Gynecol 2012	United States	Non-Hispanic white	LAMC1	rs10911193 rs1413390 rs20558 rs20563 rs10911206 rs2296291 rs12041030 rs12739316 rs3768617 rs2483675 rs10911211 rs41475048 rs1058177 rs12073936	POPQ ≥3	POPQ <2	239	197
Wu et al63	Obstet Gynecol 2012	United States	Non-Hispanic white	MMP9	rs3918253 rs3918256 rs3918278 rs17576 rs2274755 rs17577 rs2236416 rs3787268	POPQ ≥3	POPQ <2	239	197

AUA, American Urological Association; ICS, International Continence Society; IUGA, International Urogynecological Association; LUTS, lower urinary tract symptoms; OAB, overactive bladder; POP, pelvic organ prolapse; POPQ, Pelvic Organ Prolapse Quantification system; SNP, single-nucleotide polymorphism; SUI, stress urinary incontinence; UI, urinary incontinence; UUI, urge urinary incontinence.

Cartwright. Genetic association studies of LUTS and POP. Am J Obstet Gynecol 2015.

^aAssessments of descent/ethnicity/race as specified in primary publications, or from additional data from authors, or assumed for countries with low ethnic heterogeneity including Taiwan, Korea, and Japan

^bGenome-wide significant genes (P <5 × 10^-8) reported in genome-wide association study.